DOI: 10.36347/sjams.2017.v05i12.046

Pages: 5019-5023

Acute Coronary Syndrome (ACS) is a major health burden worldwide and causes more deaths and disability and incurs greater economic costs than any other illness in the world. Cystatin C is a naturally occurring protease inhibitor that protects the host tissue from cysteine proteases, which is a proatherogenic factor. Aim of our study was to assess the plasma Cystatin C concentration in patients hospitalized for ACS as there is very little literature available on the performance of Cystatin C in ACS patients of Indian population, and to investigate the relationship between Cystatin C and marker of renal function, eGFR. 100 cases presenting with ACS at our centre during study period were evaluated. The Pearson’s Chi-Square test had used to demonstrate the associations of risk factors like diabetes mellitus, hypertension, history of ischemic heart disease and smoking history of acute coronary syndrome patients with their levels of plasma Cystatin C (≤0.95 and >0.95 milligram/liter). The plasma Cystatin C level of all studied patients of ACS was obtained in the range of 0.64 mg/L to 1.94 mg/L (1.19±0.22 mg/L). Cystatin C was found to be >0.95mg/L in 88% of the total population. Our study evidenced a significant association of Cystatin C level (>0.95mg/L) with eGFR ranges. Our study evidenced a significant association between Cystatin C >0.95 mg/L with diabetes and hypertension. Of the total smokers, 94.3% were found to have Cystatin C >0.95 mg/L. Our study evidenced a negative correlation between high Cystatin C (>0.95 mg/L) and HDL levels. The determination of Cystatin C at the time of hospitalization in patients with ACS may be a good clinical tool for cardiovascular risk stratification and clinical outcomes even in patients with preserved renal function.